Literature DB >> 14595024

Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway.

Nitza G Shoham1, Michael Centola, Elizabeth Mansfield, Keith M Hull, Geryl Wood, Carol A Wise, Daniel L Kastner.   

Abstract

Pyrin, the familial Mediterranean fever protein, is found in association with the cytoskeleton in myeloid/monocytic cells and modulates IL-1beta processing, NF-kappaB activation, and apoptosis. These effects are mediated in part through cognate interactions with the adaptor protein ASC, which shares an N-terminal motif with pyrin. We sought additional upstream regulators of inflammation by using pyrin as the bait in yeast two-hybrid assays. We now show that proline serine threonine phosphatase-interacting protein [PSTPIP1, or CD2-binding protein 1 (CD2BP1)], a tyrosine-phosphorylated protein involved in cytoskeletal organization, also interacts with pyrin. Recently, PSTPIP1/CD2BP1 mutations were shown to cause the syndrome of pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA), a dominantly inherited autoinflammatory disorder mediated predominantly by granulocytes. Endogenous PSTPIP1/CD2BP1 and pyrin are coexpressed in monocytes and granulocytes and can be coimmunoprecipitated from THP-1 cells. The B box segment of pyrin was necessary and the B box/coiled-coil segment sufficient for this interaction, whereas the SH3 and coiled-coil domains of PSTPIP1/CD2BP1 were both necessary, but neither was sufficient, for pyrin binding. The Y344F PSTPIP1/CD2BP1 mutation, which blocks tyrosine phosphorylation, was associated with a marked reduction in pyrin binding in pervanadate-treated cells. PAPA-associated A230T and E250Q PSTPIP1/CD2BP1 mutations markedly increased pyrin binding as assayed by immunoprecipitation and, relative to WT, these mutants were hyperphosphorylated when coexpressed with c-Abl kinase. Consistent with the hypothesis that these mutations exert a dominant-negative effect on the previously reported activity of pyrin, we found increased IL-1beta production by peripheral blood leukocytes from a clinically active PAPA patient with the A230T PSTPIP1/CD2BP1 mutation and in cell lines transfected with both PAPA-associated mutants.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14595024      PMCID: PMC263843          DOI: 10.1073/pnas.2135380100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells.

Authors:  J Masumoto; S Taniguchi; K Ayukawa; H Sarvotham; T Kishino; N Niikawa; E Hidaka; T Katsuyama; T Higuchi; J Sagara
Journal:  J Biol Chem       Date:  1999-11-26       Impact factor: 5.157

2.  Cdc42-interacting protein 4 mediates binding of the Wiskott-Aldrich syndrome protein to microtubules.

Authors:  L Tian; D L Nelson; D M Stewart
Journal:  J Biol Chem       Date:  2000-03-17       Impact factor: 5.157

3.  A Cdc42 target protein with homology to the non-kinase domain of FER has a potential role in regulating the actin cytoskeleton.

Authors:  P Aspenström
Journal:  Curr Biol       Date:  1997-07-01       Impact factor: 10.834

4.  The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators.

Authors:  M Centola; G Wood; D M Frucht; J Galon; M Aringer; C Farrell; D W Kingma; M E Horwitz; E Mansfield; S M Holland; J J O'Shea; H F Rosenberg; H L Malech; D L Kastner
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

5.  The S. pombe cdc15 gene is a key element in the reorganization of F-actin at mitosis.

Authors:  C Fankhauser; A Reymond; L Cerutti; S Utzig; K Hofmann; V Simanis
Journal:  Cell       Date:  1995-08-11       Impact factor: 41.582

6.  Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis.

Authors:  Jae Jin Chae; Hirsh D Komarow; Jun Cheng; Geryl Wood; Nina Raben; P Paul Liu; Daniel L Kastner
Journal:  Mol Cell       Date:  2003-03       Impact factor: 17.970

7.  ASC is an activating adaptor for NF-kappa B and caspase-8-dependent apoptosis.

Authors:  Junya Masumoto; Theresa A Dowds; Philip Schaner; Felicia F Chen; Yasunori Ogura; Mu Li; Li Zhu; Tsutomu Katsuyama; Junji Sagara; Shun'ichiro Taniguchi; Deborah L Gumucio; Gabriel Núñez; Naohiro Inohara
Journal:  Biochem Biophys Res Commun       Date:  2003-03-28       Impact factor: 3.575

8.  The Wiskott-Aldrich syndrome protein acts downstream of CD2 and the CD2AP and PSTPIP1 adaptors to promote formation of the immunological synapse.

Authors:  Karen Badour; Jinyi Zhang; Fabio Shi; Mary K H McGavin; Vik Rampersad; Lynne A Hardy; Deborah Field; Katherine A Siminovitch
Journal:  Immunity       Date:  2003-01       Impact factor: 31.745

9.  A cdc15-like adaptor protein (CD2BP1) interacts with the CD2 cytoplasmic domain and regulates CD2-triggered adhesion.

Authors:  J Li; K Nishizawa; W An; R E Hussey; F E Lialios; R Salgia; R Sunder-Plassmann; E L Reinherz
Journal:  EMBO J       Date:  1998-12-15       Impact factor: 11.598

10.  PSTPIP: a tyrosine phosphorylated cleavage furrow-associated protein that is a substrate for a PEST tyrosine phosphatase.

Authors:  S Spencer; D Dowbenko; J Cheng; W Li; J Brush; S Utzig; V Simanis; L A Lasky
Journal:  J Cell Biol       Date:  1997-08-25       Impact factor: 10.539

View more
  146 in total

1.  Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne).

Authors:  Andrew P Demidowich; Alexandra F Freeman; Douglas B Kuhns; Ivona Aksentijevich; John I Gallin; Maria L Turner; Daniel L Kastner; Steven M Holland
Journal:  Arthritis Rheum       Date:  2011-12-12

Review 2.  Inflammasome-mediated autoinflammatory disorders.

Authors:  Shruti P Wilson; Suzanne L Cassel
Journal:  Postgrad Med       Date:  2010-09       Impact factor: 3.840

Review 3.  The Contribution of PTPN22 to Rheumatic Disease.

Authors:  Tomas Mustelin; Nunzio Bottini; Stephanie M Stanford
Journal:  Arthritis Rheumatol       Date:  2019-03-02       Impact factor: 10.995

Review 4.  IL-1 pathways in inflammation and human diseases.

Authors:  Cem Gabay; Céline Lamacchia; Gaby Palmer
Journal:  Nat Rev Rheumatol       Date:  2010-02-23       Impact factor: 20.543

5.  Mutation of mouse Mayp/Pstpip2 causes a macrophage autoinflammatory disease.

Authors:  Johannes Grosse; Violeta Chitu; Andreas Marquardt; Petra Hanke; Carolin Schmittwolf; Lutz Zeitlmann; Patricia Schropp; Bettina Barth; Philipp Yu; Rainer Paffenholz; Gabriele Stumm; Michael Nehls; E Richard Stanley
Journal:  Blood       Date:  2006-01-05       Impact factor: 22.113

6.  Hypothalamic proline-rich polypeptide is an oxidative burst regulator.

Authors:  Tigran K Davtyan; Hayk M Manukyan; Gagik S Hakopyan; Nana R Mkrtchyan; Samvel A Avetisyan; Armen A Galoyan
Journal:  Neurochem Res       Date:  2005-03       Impact factor: 3.996

Review 7.  The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation.

Authors:  Kalpana Manthiram; Qing Zhou; Ivona Aksentijevich; Daniel L Kastner
Journal:  Nat Immunol       Date:  2017-07-19       Impact factor: 25.606

8.  Primed innate immunity leads to autoinflammatory disease in PSTPIP2-deficient cmo mice.

Authors:  Violeta Chitu; Polly J Ferguson; Rosalie de Bruijn; Annette J Schlueter; Luis A Ochoa; Thomas J Waldschmidt; Yee-Guide Yeung; E Richard Stanley
Journal:  Blood       Date:  2009-07-16       Impact factor: 22.113

9.  Tyrosine phosphatase inhibition induces an ASC-dependent pyroptosis.

Authors:  Mohammed G Ghonime; Obada R Shamaa; Ramadan A Eldomany; Mikhail A Gavrilin; Mark D Wewers
Journal:  Biochem Biophys Res Commun       Date:  2012-07-27       Impact factor: 3.575

Review 10.  [Hereditary periodic fever].

Authors:  P Lamprecht; C Timmann; K Ahmadi-Simab; W L Gross
Journal:  Internist (Berl)       Date:  2004-08       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.